ResMed
373 hedge funds and large institutions have $5.79B invested in ResMed in 2016 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 136 increasing their positions, 136 reducing their positions, and 23 closing their positions.
65% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 23
3% more funds holding
Funds holding: 361 → 373 (+12)
1.63% more ownership
Funds ownership: 62.32% → 63.94% (+1.6%)
5% more capital invested
Capital invested by funds: $5.53B → $5.79B (+$261M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 136
19% less call options, than puts
Call options by funds: $17.3M | Put options by funds: $21.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$343M |
| 2 |
ACM
American Capital Management
New York
|
+$44.6M |
| 3 |
Renaissance Technologies
New York
|
+$42.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$38.7M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$25.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$113M |
| 2 |
PP
Prudential plc
London, England,
United Kingdom
|
-$71.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$66.1M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$33.1M |
| 5 |
T
TOBAM
Paris,
France
|
-$32.8M |
RMD Hedge Fund Activity: Q3 2016 in Review
373 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2016, worth a combined $5.79B — up 4.7% from $5.53B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RMD positions and 23 closed out — a net gain of 15 holders — while 136 added to existing stakes and 136 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $343M. The largest seller was Fidelity Investments, cutting an estimated $113M.
- 373 institutional investors held ResMed (RMD) as of Q3 2016, up from 361 in Q2 2016.
- Funds reported $5.79B of ResMed stock for Q3 2016, up 4.7% quarter-over-quarter.
- 38 funds opened new ResMed positions in Q3 2016 and 23 closed out, a net change of +15 holders.
- The largest ResMed buyer in Q3 2016 was Baillie Gifford & Co, an estimated $343M added.
- The largest ResMed seller in Q3 2016 was Fidelity Investments, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2016.